Vir Biotechnology, Inc. SEC filings VIR
Vir Biotechnology, Inc. has 801 filings in SEC EDGAR's recent list, going back to Jun 29, 2018. Its latest annual report, Form ARS, was filed on Apr 16, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 4, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| POS EX | Filing | Jul 8, 2020 | — |
| EFFECT | Filing | Jul 7, 2020 | — |
| CORRESP | Letter to the SEC | Jul 6, 2020 | — |
| CORRESP | Letter to the SEC | Jul 6, 2020 | — |
| UPLOAD | Letter from the SEC | Jun 29, 2020 | — |
| DRS | Filing | Jun 23, 2020 | — |
| D | Filing | May 8, 2020 | — |
| D | Filing | May 8, 2020 | — |
| EFFECT | Filing | Oct 10, 2019 | — |
| CERT | 8a certification | Oct 10, 2019 | — |
| 8-A12B | Filing | Oct 9, 2019 | — |
| CORRESP | Letter to the SEC | Oct 8, 2019 | — |
| CORRESP | Letter to the SEC | Oct 8, 2019 | — |
| CORRESP | Letter to the SEC | Sep 30, 2019 | — |
| SEC STAFF LETTER | Filing | Sep 20, 2019 | — |
| CORRESP | Letter to the SEC | Sep 17, 2019 | — |
| UPLOAD | Letter from the SEC | Sep 10, 2019 | — |
| CORRESP | Letter to the SEC | Sep 3, 2019 | — |
| UPLOAD | Letter from the SEC | Aug 26, 2019 | — |
| DRSLTR | Filing | Aug 7, 2019 | — |
| DRS/A | Filing | Aug 7, 2019 | — |
| UPLOAD | Letter from the SEC | Jul 25, 2019 | — |
| SEC STAFF LETTER | Filing | Jul 15, 2019 | — |
| DRS | Filing | Jun 27, 2019 | — |
| D | Filing | Jun 29, 2018 | — |
Showing 25 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- VIR (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Francisco, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1706431
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.